Log In
Print
BCIQ
Print
Print this Print this
 

Vesicare, solifenacin succinate

Also known as: YM905

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionMuscarinic M3 receptor antagonist
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients; Treat overactive bladder (OAB); Treat symptoms associated with overactive baldder syndrome
Regulatory Designation

Partner

GlaxoSmithKline plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today